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Metals in biological systems hold key roles including facilitating enzyme function, oxygen transport 
and redox chemistry. As our understanding of the role of metals in the body improves, we can 
increasingly make use of their unique properties in the development of potential novel therapies [1]. 
  
In the last half a century, metal complexes have become key to the treatment of cancer, making them 
some of the most commonly used therapeutics in the developed world. Cisplatin has proved 
unparalleled in its efficacy against tumours, interacting with DNA to trigger cell death [2]. The 
pioneering studies of Barney Rosenberg, leading to the development of cisplatin as a form of 
treatment, came unexpectedly when his group found that platinum-based electrodes could inhibit 
strains of E. coli [3]. Thanks to his relentless work in convincing industry to test platinum-based 
modalities against cancer, platinum drugs have become our most vital components in the fight against 
cancer over the last four decades and many clinical trials and combinations continue to  be conducted 
[4]. 
  
However, since Cisplatin’s approval in 1978, few further metal based medicines have reached 
circulation. While considered by the WHO an essential drug, Cisplatin has its flaws, prone to fast 
resistance build up in tumours, and with debilitating side effects through its cytotoxicity. Another 
problem lies in the lack of specificity of the active metal core, leading to undesirable biological activity 
and interactions with other biomolecules, although our improved understanding of such interactions 
may ultimately lead to more selective drugs [5]. 
  
In recent years, efforts have been made to combat these flaws. New mechanisms of delivery can 
improve the drug’s specificity by extending ligand structures, facilitating transport to the site of action 
in cancerous cells. Prodrugs offer the opportunity to incorporate multiple motifs in a single complex, 
delivering several mechanisms of action together to combat the build-up of resistance. This work has 
helped extend the interest of metallodrugs into other areas of medical research, ranging from 
antibiotics to the treatment of neurodegenerative diseases [6]. 
  
Hanif and Hartinger begin the issue by detailing cisplatin’s flaws, and discussing the steps being taken 
to fix these problems [7]. Progress in precision medicine has brought new ways to selectively target 
cancer cells, and recently researchers have attempted to use metallodrugs to trigger 
immunomodulatory effects, re-activating the anti-cancer immune response. Yang then proposes a 
simple strategy for developing effective metallodrugs, giving platinum and vanadium-based examples 
[8]. He suggests that metallodrugs work through mimicking metal regulated systems for signal 
transduction, and that drugs must incorporate ‘enhancer’ and ‘antidote’ structures, promoting 
signalling while preventing metal toxicity. 
  
Koide et al. describe their initial work on improving the metallodrug carboplatin. Koide’s team have 
begun incorporating an arginine-rich triple helical peptide motif into the complex [9]. The structure’s 
positive charge can facilitate movement through cell membranes, releasing platinum under conditions 
found in the target location. 
 
Not all research has focussed on improving existing medicines. A short communication by Spencer and 
his team, as an extension to their earlier work in related areas [10], illustrates how ferrocene-derived 
structures could be used in the future to antagonise key GPCRs [11]. Ferrocene has long been of 
interest to medicinal chemists, with its favourable lipophilicity, lack of toxicity and capacity to generate 
reactive oxygen species making it an ideal drug candidate. Ferroquine, a ferrocene-based analogue of 
chloroquine, has been effective in clinical trials against chloroquine-resistant malarial strains [12]. A 
number of other ferrocene analogues, such as ferrocifens [13], have shown promising anticancer 
action through their redox activity [14]. 
 
As an understanding of molecular recognition has improved, scientists have begun constructing 
structures to mimic the action of enzymes and important biomolecules. Cyclodextrin is an example of 
a structure of interest due to its hydrophobic cavity, which could be used to improve the bioavailability 
of lipophilic small molecules. In her joint review with Oliveri, Vecchio highlights recent efforts to 
incorporate cyclodextrin into metal complexes to build better therapeutic, diagnostic and theranostic 
drugs [15]. Indeed, while the therapeutic use of metal complexes has seen little success in the clinic, 
metals hold other positions of medical importance. MRI contrast agents, such as cardolite, are often 
now taken for granted; such is their impact in medicine and diagnosis. Gadolinium is key to MRI 
procedures and Chang discusses the development of new agents, their key features and problems 
[16]. More tailored complexes allow for more nuanced imaging, responding to different stimuli, and 
the review focuses on structures to identify blood pooling, enabling binding to specific organs or 
identify specific pathologies. 
  
In their work, Lui, Qu and Wang look to the future of metal-based medicines, targeting new classes of 
disease [17]. Alzheimer’s disease manifests itself in the form of aggregates of amyloid-β peptide, 
forming plaques in and around dendritic neurons. There is hope that metal chelators could be used 
therapeutically, coordinating to Cu(II), Zn(II), and Fe(III) residues in the peptide structure to prevent 
or reverse aggregation. Scaffolds binding to these metal cores could also aid the imaging of plaques, 
combining both properties for theranostic purposes.  
 
It has been a pleasure to guest edit this exciting volume of Future Medicinal Chemistry, which brings 
together a broad variety of articles involving the use of metals in biological systems, and illustrates 
the potential for extending their functionality and scope not only in fundamental but also in applied 
science. 
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